PhoenixBio Co., Ltd. (TYO:6190)
Japan · Delayed Price · Currency is JPY 338.00
-4.00 (-1.17%)
Aug 27, 2026, 3:30 PM JST
PhoenixBio Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 1,103 | 1,147 | 1,149 | 1,384 | 1,555 | 1,325 |
Short-Term Investments | 1 | 1 | - | - | - | - |
Cash & Short-Term Investments | 1,104 | 1,148 | 1,149 | 1,384 | 1,555 | 1,325 |
Cash Growth | 6.67% | -0.09% | -16.98% | -11.00% | 17.36% | -0.15% |
Receivables | 76 | 136 | 170 | 217 | 286 | 226 |
Inventory | 297 | 307 | 333 | 450 | 365 | 258 |
Other Current Assets | 50 | 52 | 65 | 81 | 86 | 45 |
Total Current Assets | 1,527 | 1,643 | 1,717 | 2,132 | 2,292 | 1,854 |
Property, Plant & Equipment | 511 | 518 | 527 | 542 | 538 | 409 |
Long-Term Investments | 16 | 12 | 12 | 15 | 145 | 11 |
Other Intangible Assets | 13 | 14 | 18 | 10 | 5 | 1 |
Long-Term Deferred Tax Assets | - | 3 | 9 | 14 | 37 | 3 |
Other Long-Term Assets | 1 | 2 | 2 | 2 | 1 | 2 |
Total Assets | 2,068 | 2,192 | 2,285 | 2,715 | 3,018 | 2,280 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 12 | 13 | 16 | 12 | 40 | 37 |
Accrued Expenses | 1 | 6 | 7 | 7 | 4 | - |
Short-Term Debt | 100 | 110 | 100 | 100 | - | - |
Current Portion of Long-Term Debt | 79 | 79 | 79 | 79 | 875 | - |
Current Portion of Leases | - | 30 | 32 | 52 | 40 | 30 |
Current Income Taxes Payable | 3 | 10 | 11 | 4 | 63 | 12 |
Other Current Liabilities | 169 | 125 | 321 | 167 | 264 | 359 |
Total Current Liabilities | 364 | 373 | 566 | 421 | 1,286 | 438 |
Long-Term Debt | 120 | 140 | 220 | 300 | - | 900 |
Long-Term Leases | - | 126 | 133 | 191 | 214 | 107 |
Long-Term Deferred Tax Liabilities | - | - | - | 1 | - | - |
Other Long-Term Liabilities | 121 | 1 | 2 | 6 | 4 | 7 |
Total Liabilities | 605 | 640 | 921 | 919 | 1,504 | 1,452 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 2,573 | 2,573 | 2,569 | 2,562 | 2,453 | 2,363 |
Additional Paid-In Capital | 793 | 793 | 789 | 782 | 673 | 583 |
Retained Earnings | -1,998 | -1,907 | -2,032 | -1,584 | -1,610 | -2,103 |
Comprehensive Income & Other | 95 | 93 | 38 | 36 | -2 | -15 |
Shareholders' Equity | 1,463 | 1,552 | 1,364 | 1,796 | 1,514 | 828 |
Total Liabilities & Equity | 2,068 | 2,192 | 2,285 | 2,715 | 3,018 | 2,280 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 299 | 485 | 564 | 722 | 1,129 | 1,037 |
Net Cash (Debt) | 805 | 663 | 585 | 662 | 426 | 288 |
Net Cash Growth | 22.71% | 13.33% | -11.63% | 55.40% | 47.92% | -0.69% |
Net Cash Per Share | 197.80 | 163.11 | 144.64 | 175.05 | 84.01 | 87.22 |
Filing Date Shares Outstanding | 4.07 | 4.07 | 4.05 | 4.03 | 3.63 | 3.31 |
Total Common Shares Outstanding | 4.07 | 4.07 | 4.05 | 4.03 | 3.63 | 3.31 |
Working Capital | 1,163 | 1,270 | 1,151 | 1,711 | 1,006 | 1,416 |
Book Value Per Share | 359.44 | 381.31 | 336.75 | 445.87 | 416.65 | 250.37 |
Tangible Book Value | 1,450 | 1,538 | 1,346 | 1,786 | 1,509 | 827 |
Tangible Book Value Per Share | 356.25 | 377.87 | 332.30 | 443.39 | 415.27 | 250.07 |
Order Backlog | - | 616.11 | 1,098 | 714.23 | 454.65 | 1,168 |